![](/img/cover-not-exists.png)
PGI12 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Fioratti, C., Rachid, M.L., Baida, R., Decimoni, T., Brunelli, M.J.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.1135
Date:
November, 2019
File:
PDF, 381 KB
2019